<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Geert</forename><surname>Robaeys</surname></persName>
							<email>geert.robaeys@zol.be</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Ziekenhuis Oost Limburg</orgName>
								<address>
									<settlement>Genk</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Hepatology UZ Leuven</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Faculty of Medicine and Life Sciences</orgName>
								<orgName type="institution" key="instit1">Limburg Clinical Research Program</orgName>
								<orgName type="institution" key="instit2">Hasselt University</orgName>
								<address>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jason</forename><surname>Grebely</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Kirby Institute</orgName>
								<orgName type="institution" key="instit2">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Mauss</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for HIV and Hepatogastroenterology</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philip</forename><surname>Bruggmann</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Arud Centres of Addiction Medicine</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><surname>Moussalli</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Hôpital Pitié-Salpêtrière</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Université Pierre et Marie Curie</orgName>
								<address>
									<addrLine>Paris VI</addrLine>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>De Gottardi</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Clinic of Visceral Surgery and Medicine</orgName>
								<address>
									<settlement>Hepatology, Inselspital, Berne</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tracy</forename><surname>Swan</surname></persName>
							<affiliation key="aff9">
								<orgName type="laboratory">Treatment Action Group</orgName>
								<address>
									<settlement>New York</settlement>
									<region>New York</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amber</forename><surname>Arain</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Ziekenhuis Oost Limburg</orgName>
								<address>
									<settlement>Genk</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Faculty of Medicine and Life Sciences</orgName>
								<orgName type="institution" key="instit1">Limburg Clinical Research Program</orgName>
								<orgName type="institution" key="instit2">Hasselt University</orgName>
								<address>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Achim</forename><surname>Kautz</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">European Liver Patients Association</orgName>
								<address>
									<settlement>Cologne</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heino</forename><surname>Stöver</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Institute of Addiction Research</orgName>
								<orgName type="institution">University of Applied Sciences</orgName>
								<address>
									<settlement>Frankfurt am Main</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heiner</forename><surname>Wedemeyer</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Gastroenterology, Hepatology and Endocrinology</orgName>
								<orgName type="institution">University of Hannover</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Schaefer</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Psychiatry, Psychotherapy and Addiction Medicine</orgName>
								<orgName type="institution">Kliniken Essen-Mitte</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Psychiatry and Psychotherapy-CCM</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lynn</forename><surname>Taylor</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Brown University</orgName>
								<address>
									<settlement>Providence, Rhode Island</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Backmund</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Ludwig-Maximilians-University</orgName>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">Praxiszentrum im Tal Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olav</forename><surname>Dalgard</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">Akershus University Hospital</orgName>
								<address>
									<settlement>Lørenskog</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Prins</surname></persName>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Department of Research</orgName>
								<orgName type="department" key="dep2">Cluster Infectious Diseases</orgName>
								<orgName type="department" key="dep3">Public Health Service of Amsterdam</orgName>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Center for Infection and Immunity Amsterdam</orgName>
								<orgName type="institution">Academic Medical Centre</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gregory</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department">HIV/Immunology/Infectious Diseases Clinical Services Unit</orgName>
								<orgName type="institution">St Vincent&apos;s Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Professor of Medicine and Life Sci-ences</orgName>
								<orgName type="department" key="dep2">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Ziekenhuis Oost Limburg</orgName>
								<address>
									<addrLine>Schiepse Bos 6</addrLine>
									<postCode>B 3600</postCode>
									<settlement>Genk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4278865FB6525AB9E70F345666E98246</idno>
					<idno type="DOI">10.1093/cid/cit302</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>drug users</term>
					<term>injecting</term>
					<term>injection</term>
					<term>guidelines</term>
					<term>HCV</term>
					<term>HIV</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID).</s><s>The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low.</s><s>Among PWID, there are a number of barriers to care that should be considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment.</s><s>Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings.</s><s>Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed.</s><s>These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment.</s><s>Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new treatments for HCV infection become available.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>In the developed world, 50%-80% of hepatitis C virus (HCV) infection is among people who inject drugs (PWID) <ref type="bibr" target="#b0">[1]</ref>.</s><s>Hereafter, "PWID" will refer to people with current or "active" injection drug use (IDU), which is generally defined as use in the past 6 months, and to former injectors who are still active noninjection drug users and/or on opioid substitution therapy (OST).</s><s>The natural history of HCV (increase in liver cirrhosis after 15-20 years), and an aging cohort of PWID, means that a large burden of advanced liver disease is anticipated in the next decade <ref type="bibr" target="#b1">[2]</ref>.</s></p><p><s>Until recently, HCV treatment guidelines excluded PWID, due to concerns about poor adherence, adverse events, and reinfection <ref type="bibr" target="#b2">[3]</ref>.</s><s>Successful HCV treatment studies among PWID challenged this paradigm , and guidelines have been revised to consider HCV treatment among PWID on a "case-by-case" basis <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>.</s></p><p><s>Despite revised guidelines, few PWID have received HCV treatment <ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b40">[40]</ref><ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref>.</s><s>Enhanced HCV assessment and treatment in PWID will be required to reduce future HCV-related morbidity and mortality <ref type="bibr" target="#b43">[43]</ref>.</s><s>The availability of effective, tolerable, and simpler direct-acting antivirals (DAAs) should improve the feasibility of this approach.</s><s>The International Network of Hepatitis in Substance Users established an expert panel to develop recommendations to enhance HCV assessment, management, and treatment among PWID.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>The recommendations have been graded according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, <ref type="bibr" target="#b37">[38]</ref>.</s><s>The strength of recommendations reflects the quality of underlying evidence (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The quality of the evidence has been classified in 1 of 3 levels: high (A), moderate (B), or low (C).</s><s>The GRADE system offers 2 grades of recommendation: strong (1) or weak <ref type="bibr" target="#b1">(2)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Epidemiology and Prevention of HCV</head><p><s>Prevalence of HCV among PWID is 65% <ref type="bibr" target="#b44">[44]</ref> and &gt;80% among long-term PWID <ref type="bibr" target="#b45">[45]</ref>.</s><s>HCV genotypes 1a, 1b, and 3a are common among PWID <ref type="bibr" target="#b46">[46]</ref>.</s><s>Genotype 4d is common among PWID in Europe <ref type="bibr" target="#b47">[47]</ref>, and 6 in Southeast Asia <ref type="bibr" target="#b48">[48]</ref>.</s><s>Incidence of HCV in PWID is 2%-45% per annum <ref type="bibr" target="#b45">[45]</ref>.</s><s>High coverage of combined harm reduction programs (opioid substitution treatment [OST] and needle exchange programs) can reduce HCV incidence <ref type="bibr" target="#b49">[49]</ref><ref type="bibr" target="#b50">[50]</ref><ref type="bibr" target="#b51">[51]</ref>.</s><s>Modeling studies suggest that HCV treatment for PWID could reduce transmission <ref type="bibr" target="#b52">[52]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p><s>1. PWID should be routinely and voluntarily tested for HCV antibodies/RNA and if negative, every 6-12 months (B1).</s></p><p><s>2. PWID should be provided with clean drug injecting equipment and access to OST as part of widespread comprehensive harm reduction programs, including in prisons (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Natural History of HCV and Effects of Drugs on the Liver</head><p><s>Chronic HCV infection develops in 75% <ref type="bibr" target="#b53">[53]</ref>, with 10%-20% developing cirrhosis over 20-30 years of infection <ref type="bibr" target="#b1">[2]</ref>.</s><s>In a meta-analysis of HCV-infected PWID, the 20-year cirrhosis prevalence was 15% <ref type="bibr" target="#b54">[54]</ref>.</s><s>Despite slow HCV disease progression over the initial 20 years of infection, factors contributing to fibrosis progression include age, continued moderate to heavy alcohol use, human immunodeficiency virus (HIV) infection, obesity, and insulin resistance (reviewed in <ref type="bibr" target="#b1">[2]</ref>).</s></p><p><s>Despite misconceptions among affected populations and healthcare workers, no liver toxicity is reported for heroin <ref type="bibr" target="#b55">[55]</ref> or methadone <ref type="bibr" target="#b56">[56]</ref>.</s><s>Buprenorphine occasionally increases transaminases <ref type="bibr" target="#b57">[57]</ref>.</s><s>Methylenedioxymethamphetamine rarely causes acute liver failure due to direct liver toxicity <ref type="bibr" target="#b58">[58,</ref><ref type="bibr" target="#b59">59]</ref>, and little is known about methamphetamine-related liver toxicity <ref type="bibr" target="#b60">[60]</ref>.</s><s>Heavy alcohol consumption is associated with a higher risk of cirrhosis <ref type="bibr" target="#b61">[61]</ref>.</s><s>Tobacco <ref type="bibr" target="#b62">[62]</ref> and daily cannabis <ref type="bibr" target="#b63">[63,</ref><ref type="bibr" target="#b64">64]</ref> smoking may increase fibrosis progression, but further studies are needed.</s><s>Coffee consumption is associated with lower necroinflammatory activity and less-advanced fibrosis <ref type="bibr" target="#b65">[65,</ref><ref type="bibr" target="#b66">66]</ref>.</s></p><p><s>Aging cohorts of PWID with chronic HCV and low treatment uptake are currently leading to an increasing burden of HCV-related morbidity and mortality <ref type="bibr" target="#b1">[2]</ref>.</s><s>In several countries where PWID are the major population affected by HCV, 20%-25% of deaths among HCV-infected individuals are from liver disease and 15%-30% are from drug-related causes <ref type="bibr" target="#b1">[2]</ref>.</s><s>Recommendations 1. PWID should be counseled to moderate alcohol intake, or abstain if there is evidence of advanced liver disease (A1).</s></p><p><s>2. PWID should be counseled to moderate cannabis use, or abstain if there is evidence of advanced liver disease (B2).</s></p><p><s>3. Cessation of injecting is not required to limit HCV disease progression (B2).</s></p><p><s>4. The potential impact of drug use on the liver should be discussed with PWID (C2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Noninvasive Liver Fibrosis Assessment</head><p><s>Liver biopsy is the gold standard for liver fibrosis assessment, but it is invasive and logistically difficult.</s><s>As per international guidelines <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>, noninvasive methods such as transient elastography or well-established panels of biomarkers of fibrosis are acceptable for liver disease assessment.</s><s>Noninvasive methods have excellent utility for the identification of HCV-related cirrhosis, but lesser accuracy for earlier stages <ref type="bibr" target="#b67">[67]</ref>, and can predict HCV-related survival <ref type="bibr" target="#b68">[68]</ref>.</s><s>Combining multiple modalities achieves the best performance <ref type="bibr" target="#b69">[69]</ref>.</s><s>Noninvasive tests are cost-effective <ref type="bibr" target="#b70">[70]</ref>.</s><s>Among PWID, transient elastography can enhance liver disease screening <ref type="bibr" target="#b71">[71,</ref><ref type="bibr" target="#b72">72]</ref>.</s></p><p><s>Recommendations 1. Noninvasive assessments have a reduced risk and greater acceptance than liver biopsy, may enhance HCV screening and disease assessment among PWID, and should be offered, if available (B1).</s></p><p><s>2. Combining multiple noninvasive assessments is recommended, when possible (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pretherapeutic Assessment</head><p><s>Guidelines for pretherapeutic assessment for those with HCV are available <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>.</s><s>However, HCV-infected PWID have complex social, medical, and psychiatric comorbidities, complicating decisions around care (reviewed in <ref type="bibr" target="#b73">[73]</ref>).</s><s>Poor HCV knowledge and inaccurate perceptions are barriers for accessing care <ref type="bibr" target="#b74">[74]</ref><ref type="bibr" target="#b75">[75]</ref><ref type="bibr" target="#b76">[76]</ref><ref type="bibr" target="#b77">[77]</ref>.</s><s>Factors associated with not receiving HCV treatment include older age <ref type="bibr" target="#b78">[78]</ref>, minority ethnicity <ref type="bibr" target="#b78">[78]</ref>, ongoing or former drug use <ref type="bibr" target="#b79">[79]</ref><ref type="bibr" target="#b80">[80]</ref><ref type="bibr" target="#b81">[81]</ref>, ongoing alcohol use <ref type="bibr" target="#b78">[78,</ref><ref type="bibr" target="#b79">79]</ref>, advanced liver disease <ref type="bibr" target="#b80">[80]</ref>, comorbid diseases <ref type="bibr" target="#b78">[78,</ref><ref type="bibr" target="#b81">81]</ref>, psychiatric disease <ref type="bibr" target="#b78">[78,</ref><ref type="bibr" target="#b80">80]</ref>, and OST <ref type="bibr" target="#b79">[79]</ref>.</s></p><p><s>Recommendations 1. Pretherapeutic education should include discussions of HCV transmission, risk factors for fibrosis progression, treatment, reinfection risk, and harm reduction strategies (B1).</s></p><p><s>2. Pretherapeutic assessment should include an evaluation of housing, education, cultural issues, social functioning and support, finances, nutrition, and drug and alcohol use.</s><s>PWID should be linked to social support services and peer support, if available (A1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Indications for Treatment</head><p><s>The goal of HCV therapy is to prevent liver disease complications and death from HCV.</s><s>The end point is sustained virologic response (SVR), which equates to cure in &gt;99% of patients.</s><s>SVR is associated with improved quality of life, regression of fibrosis, and reduced risk of complications in patients with cirrhosis <ref type="bibr" target="#b82">[82]</ref>.</s></p><p><s>According to international guidelines <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>, individuals with chronic HCV and absolute contraindications to standard of care should not receive therapy.</s><s>Recommendations 1. PWID should receive HCV assessment, with treatment decisions based on an individualized evaluation of social, lifestyle, and clinical factors (B1).</s></p><p><s>2. PWID with absolute contraindications to standard of care should not receive HCV therapy (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Peginterferon and DAA-Based Treatment</head><p><s>In PWID, treatment of chronic HCV with pegylated interferon alfa ( peg-IFN)/ribavirin (RBV) is safe and effective , and has been recommended for PWID by international guidelines following individualized assessment <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>.</s><s>DAA therapy, when added to peg-IFN/RBV, enhances treatment response for chronic HCV genotype 1 <ref type="bibr" target="#b83">[83]</ref><ref type="bibr" target="#b84">[84]</ref><ref type="bibr" target="#b85">[85]</ref><ref type="bibr" target="#b86">[86]</ref>.</s><s>Future DAAs in combination with peg-IFN/RBV should provide improved efficacy, tolerability, dosing schedules, and therapy duration <ref type="bibr" target="#b87">[87]</ref>.</s><s>Evidence suggests that IFN-free DAA-based regimens are likely to be curative in a high proportion of individuals with chronic HCV genotype 2/3 <ref type="bibr" target="#b88">[88,</ref><ref type="bibr" target="#b89">89]</ref> and 1 <ref type="bibr" target="#b90">[90]</ref><ref type="bibr" target="#b91">[91]</ref><ref type="bibr" target="#b92">[92]</ref> infections.</s></p><p><s>DAA clinical development programs have excluded individuals with active drug use, but many trials have included those on OST.</s><s>DAA-based safety and treatment outcome data have not been presented on clinical trial subpopulations of individuals on OST.</s><s>Drug-drug interaction studies have been undertaken on telaprevir and boceprevir with methadone <ref type="bibr" target="#b93">[93,</ref><ref type="bibr" target="#b94">94]</ref> and buprenorphine <ref type="bibr" target="#b94">[94,</ref><ref type="bibr" target="#b95">95]</ref>, with no clinically important interactions observed.</s><s>Recommendations 1. Evaluation of safety and efficacy of telaprevir and boceprevir, in combination with peg-IFN/RBV, is required in PWID with chronic HCV genotype 1 (C1).</s></p><p><s>2. Telaprevir and boceprevir can be used in PWID on OST (B1).</s></p><p><s>3. Telaprevir and boceprevir do not require specific methadone and buprenorphine dose adjustment, but patients should be monitored for signs of opioid toxicity or withdrawal (B1).</s></p><p><s>4. Consideration of telaprevir and boceprevir use in PWID should be undertaken on an individualized basis, but those with early liver disease should generally be advised to await further data and/or potential development of improved DAAbased therapies (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of Drug Use on Adherence and SVR</head><p><s>Adherence to HCV therapy is often defined as receipt of ≥80% of scheduled peg-IFN/RBV for ≥80% of the treatment period, but this does not distinguish between missed doses and treatment discontinuation <ref type="bibr" target="#b96">[96]</ref>.</s><s>Suboptimal peg-IFN exposure is driven by early treatment discontinuation as compared to missed doses <ref type="bibr" target="#b97">[97]</ref>.</s><s>Both physicians <ref type="bibr" target="#b98">[98]</ref> and individuals <ref type="bibr" target="#b99">[99]</ref> overestimate adherence to HCV therapy.</s><s>Adherence <ref type="bibr" target="#b96">[96,</ref><ref type="bibr" target="#b97">97]</ref> and treatment completion <ref type="bibr" target="#b96">[96]</ref><ref type="bibr" target="#b97">[97]</ref><ref type="bibr" target="#b98">[98]</ref> are associated with SVR, but the impact of missed doses on SVR is unclear <ref type="bibr" target="#b96">[96,</ref><ref type="bibr" target="#b97">97]</ref>.</s><s>Among PWID, adherence <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b97">97,</ref><ref type="bibr" target="#b100">100]</ref> and treatment completion <ref type="bibr" target="#b97">[97]</ref> are associated with SVR.</s></p><p><s>Peg-IFN/RBV is safe and effective among those with a history of IDU <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref> and among active PWID <ref type="bibr" target="#b101">[101]</ref>, with SVR of 54%-56% <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b101">101]</ref>.</s><s>PWID often have characteristics associated with favorable HCV treatment response, including younger age, HCV genotype 3, and mild liver disease <ref type="bibr" target="#b8">[9]</ref>.</s><s>A history of IDU does not compromise adherence <ref type="bibr" target="#b97">[97,</ref><ref type="bibr" target="#b98">98,</ref><ref type="bibr" target="#b102">102]</ref>, treatment completion <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b97">97]</ref>, or SVR <ref type="bibr" target="#b3">[4]</ref>, although some studies have found lower treatment completion <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>Recent drug use at treatment initiation has limited impact on adherence <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b97">97,</ref><ref type="bibr" target="#b98">98,</ref><ref type="bibr" target="#b100">100,</ref><ref type="bibr" target="#b103">103]</ref>, treatment completion <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b97">97]</ref>, or SVR <ref type="bibr">[6, 7, 20, 24, 27-29, 35, 101]</ref>.</s><s>Some studies have reported lower treatment completion in patients with recent drug use at treatment completion <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b31">32]</ref>.</s><s>HCV treatment does not have an impact on drug dependency treatment or increase drug use <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s>Occasional drug use during treatment does not seem to impact adherence <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b97">97,</ref><ref type="bibr" target="#b100">100]</ref>, treatment completion <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b97">97,</ref><ref type="bibr" target="#b104">104]</ref>, or SVR <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b34">35]</ref>.</s><s>However, lower adherence <ref type="bibr" target="#b97">[97,</ref><ref type="bibr" target="#b98">98]</ref> and SVR <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b23">24]</ref> have been observed in persons with frequent drug use (daily/every other day) during treatment.</s><s>When discontinuation occurs, it often occurs early during therapy <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b97">97]</ref>.</s><s>In adherent PWID, alcohol use does not impact SVR <ref type="bibr" target="#b105">[105,</ref><ref type="bibr" target="#b106">106]</ref>.</s></p><p><s>Factors independently associated with adherence and treatment completion among PWID include lower education and unstable housing <ref type="bibr" target="#b97">[97]</ref>.</s><s>Factors independently associated with lower SVR among PWID include poor social functioning <ref type="bibr" target="#b6">[7]</ref>, a history of untreated depression <ref type="bibr" target="#b32">[33]</ref>, and ongoing drug use during treatment <ref type="bibr" target="#b32">[33]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Adherence should consider missed doses and treatment discontinuation (B1).</head><p><s>2. PWID should be counseled on the importance of adherence in attaining SVR (A1).</s></p><p><s>3. HCV treatment can be considered for PWID, provided they wish to receive treatment and are able and willing to maintain regular appointments (A1).</s></p><p><s>4. A history of IDU and recent drug use at treatment initiation are not associated with reduced SVR, and decisions to treat must be made on a case-by-case basis (B1).</s></p><p><s>5. PWID with ongoing social issues or history of psychiatric disease and those with more frequent drug use during therapy are at risk of lower adherence and SVR and need to be monitored closely during therapy (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of Mental Health on Adherence and SVR</head><p><s>As reviewed in <ref type="bibr" target="#b107">[107]</ref>, psychiatric comorbidity is high among PWID.</s><s>However, PWID do not have an increased risk for the development of major depression during peg-IFN treatment.</s><s>Poorer social functioning is associated with new-onset depression during peg-IFN treatment <ref type="bibr" target="#b108">[108]</ref>.</s><s>Psychiatric comorbidity is not associated with lower adherence, treatment completion, SVR, or depression during peg-IFN treatment <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b108">[108]</ref><ref type="bibr" target="#b109">[109]</ref><ref type="bibr" target="#b110">[110]</ref><ref type="bibr" target="#b111">[111]</ref><ref type="bibr" target="#b112">[112]</ref><ref type="bibr" target="#b113">[113]</ref>.</s></p><p><s>As reviewed in <ref type="bibr" target="#b107">[107]</ref>, psychiatric contraindications to HCV therapy include acute major and uncontrolled psychiatric disorders.</s><s>Although data are conflicting, studies show that prophylactic antidepressants can reduce IFN-induced depression, particularly in patients with previous or ongoing depression <ref type="bibr" target="#b107">[107]</ref>.</s><s>Depression-specific symptoms are responsive to serotonergic antidepressants <ref type="bibr" target="#b107">[107]</ref>.</s><s>Psychiatric adverse events related to peg-IFN can be managed without dose adjustment or discontinuation.</s></p><p><s>Recommendations 1. Pretreatment assessment should include an evaluation of previous or current psychiatric illness, engagement with a drug and alcohol counselor or psychiatrist, and discussions around potential treatment options (A1).</s></p><p><s>2. If psychiatric comorbidities are present, decisions to treat with peg-IFN must be made on a case-by-case basis (A1).</s></p><p><s>3. In cases of acute major and uncontrolled psychiatric disorders, a pretreatment psychiatric assessment is recommended (C2).</s></p><p><s>4. Prophylactic antidepressants are recommended in cases of a history of IFN-induced depression and with depressive symptoms at baseline (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Management</head><p><s>HCV treatment has been delivered successfully to PWID through various models, including within hospital-based clinics, drug detoxification clinics, OST clinics, prisons, and community-based clinics.</s><s>As reviewed in <ref type="bibr" target="#b114">[114]</ref>, strategies that have been successful for enhancing assessment, adherence, or SVR include hospital-based and primary care-based integrated care, community-based telehealth, nurse-led education, psychoeducation, directly observed therapy, peer support groups, and peer support workers.</s><s>The key basis for effective HCV clinical management within these settings is access to a multidisciplinary team, generally including clinician and nursing clinical assessment and monitoring, drug and alcohol services, psychiatric services, and social work and other social support services (including peer support, if available).</s><s>Recommendations 1. HCV treatment for PWID should be considered on an individualized basis and delivered within a multidisciplinary team setting (B1).</s></p><p><s>2. Access to harm reduction programs, social work, and social support services should be a component of HCV clinical management (B2).</s></p><p><s>3. Peer-based support should be evaluated as a means to improve HCV clinical management (B2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reinfection Following Successful HCV Treatment</head><p><s>There is still some concern that reinfection due to recurrent risk behaviors may negate potential benefits of treatment.</s><s>Reported rates of reinfection following successful HCV treatment among PWID are low, with estimates generally 1%-5% risk per year (reviewed in <ref type="bibr" target="#b115">[115]</ref>).</s><s>Recommendations 1. PWID should not be excluded from HCV treatment on the basis of perceived risk of reinfection (B1).</s></p><p><s>2. Harm reduction education and counseling should be provided for PWID in the context of HCV treatment (B1).</s></p><p><s>3. Following SVR, monitoring for HCV reinfection through annual HCV RNA assessment should be undertaken on PWID with ongoing risk behavior (B2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment of Acute HCV</head><p><s>Acute HCV infection refers to the period spanning the first 6 months following exposure to HCV <ref type="bibr" target="#b116">[116]</ref>.</s><s>Spontaneous clearance occurs in 25% <ref type="bibr" target="#b53">[53]</ref>.</s><s>Peg-IFN-based SVR among HCVmonoinfected PWID with acute HCV is 55%-74% (reviewed in <ref type="bibr" target="#b116">[116]</ref>), with treatment outcomes associated with adherence and social support, but not IDU prior to or during treatment <ref type="bibr" target="#b6">[7]</ref>.</s><s>Recommendations 1. PWID with acute HCV symptoms should be monitored for 12-16 weeks (including HCV RNA levels) to allow potential spontaneous clearance (A1).</s></p><p><s>2. Peg-IFN monotherapy for 24 weeks should be considered for PWID with acute HCV (B1).</s></p><p><s>3. Strategies to optimize adherence should be used in the setting of acute HCV, with consideration of directly observed peg-IFN therapy (B2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HIV/HCV Coinfection</head><p><s>Prevalence of HCV among HIV-infected PWID is high (&gt;80%) <ref type="bibr" target="#b117">[117]</ref>.</s><s>Chronic HCV is the leading cause of non-AIDS death where combination antiretroviral therapy (cART) is accessible <ref type="bibr" target="#b119">[118]</ref>.</s><s>Challenges with HIV/HCV include accelerated HCV disease progression, potential cART-related liver toxicity, multiple medication requirements, drug-drug interactions, and medical comorbidities (reviewed in <ref type="bibr" target="#b120">[119]</ref>).</s><s>HIV/HCV is associated with a higher prevalence of psychiatric disorders, poverty, homelessness, and incarceration <ref type="bibr" target="#b121">[120]</ref>.</s><s>HCV treatment responses may be poorer in those with HIV/HCV <ref type="bibr" target="#b122">[121,</ref><ref type="bibr" target="#b123">122]</ref>.</s><s>Recommendations 1. HCV-infected PWID should be screened for HIV (B1).</s><s>2. The accelerated HCV disease progression in HIV/HCV should be considered in treatment decision making (B2).</s></p><p><s>3. Potential drug-drug interactions between HIV, HCV, and OST need to be considered (A1).</s><s>4. Early introduction of cART should be considered (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Management of Hepatitis B Virus Coinfection</head><p><s>The global prevalence of chronic hepatitis B virus (HBV) is 8% among PWID <ref type="bibr" target="#b44">[44]</ref>.</s><s>HBV vaccination is effective among PWID, and accelerated schedules improve adherence <ref type="bibr" target="#b124">[123]</ref>.</s><s>Peg-IFN/ RBV is effective for the treatment of HCV in persons with HBV/HCV <ref type="bibr" target="#b125">[124]</ref>.</s><s>Hepatitis D virus coinfection is frequent in PWID <ref type="bibr" target="#b126">[125]</ref>.</s><s>Peg-IFN is the only effective drug <ref type="bibr" target="#b127">[126]</ref>.</s></p><p><s>Recommendations 1. PWID should be vaccinated for hepatitis A virus and HBV (A1).</s></p><p><s>2. PWID with active HBV/HCV coinfection should be considered for peg-IFN/RBV therapy (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver Transplantation</head><p><s>The proportion of people with a history of IDU undergoing liver transplant for HCV-related cirrhosis or hepatocellular carcinoma is 5%-10% <ref type="bibr" target="#b128">[127,</ref><ref type="bibr" target="#b129">128]</ref>.</s><s>Relapse to drug use following transplant is rare <ref type="bibr" target="#b128">[127,</ref><ref type="bibr" target="#b129">128]</ref>.</s><s>Selection criteria for liver transplantation include 6-24 months of drug abstinence, controlled psychiatric disease, and the presence of stable social support networks <ref type="bibr" target="#b130">[129]</ref>.</s><s>OST is not a contraindication <ref type="bibr" target="#b128">[127,</ref><ref type="bibr" target="#b130">129,</ref><ref type="bibr" target="#b131">130]</ref>.</s><s>There are no data in PWID.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p><s>1. Awareness should be raised that liver transplant is a therapeutic option in those with a history of IDU (B2).</s></p><p><s>2. OST is not a contraindication for liver transplantation, and individuals on OST should not be advised to reduce or stop therapy (A1).</s></p><p><s>3. Psychiatric evaluation and follow-up should be offered to PWID undergoing liver transplant (B1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed.</s><s>These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment.</s><s>However, many studies performed among PWID to date are limited, given retrospective designs, small sample sizes, and lack of randomized controlled trial design.</s><s>Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new DAAs become available.</s><s>This will be crucial in the efforts to stem the burden of HCVrelated liver disease worldwide.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Notes</head><p><s>Supplement sponsorship.</s><s>This article was published as part of a supplement entitled "Prevention and Management of Hepatitis C Virus Among People Who Inject Drugs: Moving the Agenda Forward," sponsored by an unrestricted grant from the International Network on Hepatitis in Substance Users (INHSU), The Kirby Institute (University of New South Wales), Abbvie, Gilead Sciences, Janssen-Cilag, and Merck.</s></p><p><s>Potential conflicts of interest.</s><s>All authors: No reported conflicts.</s><s>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</s><s>Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Evidence Grading (Adapted From the GRADE System)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Quality of</cell></row><row><cell></cell><cell></cell><cell>Evidence/</cell></row><row><cell>Evidence</cell><cell>Notes</cell><cell>Grade</cell></row><row><cell>High quality</cell><cell>Further research is very</cell><cell>A</cell></row><row><cell></cell><cell>unlikely to change our</cell><cell></cell></row><row><cell></cell><cell>confidence in the estimate</cell><cell></cell></row><row><cell></cell><cell>of effect.</cell><cell></cell></row><row><cell>Moderate</cell><cell>Further research is likely to</cell><cell>B</cell></row><row><cell>quality</cell><cell>have an important impact on</cell><cell></cell></row><row><cell></cell><cell>our confidence in the</cell><cell></cell></row><row><cell></cell><cell>estimate of effect and may</cell><cell></cell></row><row><cell></cell><cell>change the estimate.</cell><cell></cell></row><row><cell>Low quality</cell><cell>Further research is very likely</cell><cell>C</cell></row><row><cell></cell><cell>to have an important impact</cell><cell></cell></row><row><cell></cell><cell>on our confidence in the</cell><cell></cell></row><row><cell></cell><cell>estimate of effect and is</cell><cell></cell></row><row><cell></cell><cell>likely to change the</cell><cell></cell></row><row><cell></cell><cell>estimate. Any change of</cell><cell></cell></row><row><cell></cell><cell>estimate is uncertain.</cell><cell></cell></row><row><cell cols="2">Recommendation Notes</cell><cell></cell></row><row><cell>Strong</cell><cell>Factors influencing the</cell><cell>1</cell></row><row><cell></cell><cell>strength of the</cell><cell></cell></row><row><cell></cell><cell>recommendation included</cell><cell></cell></row><row><cell></cell><cell>the quality of the evidence,</cell><cell></cell></row><row><cell></cell><cell>presumed patient-important</cell><cell></cell></row><row><cell></cell><cell>outcomes, and cost.</cell><cell></cell></row><row><cell>Weak</cell><cell>Variability in preferences and</cell><cell></cell></row><row><cell></cell><cell>values, or more uncertainty.</cell><cell></cell></row><row><cell></cell><cell>Recommendation is made</cell><cell></cell></row><row><cell></cell><cell>with less certainty, higher</cell><cell></cell></row><row><cell></cell><cell>cost, or resource</cell><cell></cell></row><row><cell></cell><cell>consumption.</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2">   S130  • CID 2013:57 (Suppl 2) •Robaeys et al   </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">S132• CID 2013:57 (Suppl 2) •Robaeys et al   </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Management of HCV Infection Among PWID • CID 2013:57 (Suppl 2) • S133</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global epidemiology of hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Shepard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Finelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Alter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="558" to="567" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">is killing people with hepatitis C virus infection?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Seminars Liver Dis</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="331" to="339" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C</title>
	</analytic>
	<monogr>
		<title level="j">National Institutes of Health</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="2S" to="10" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>Hepatology. suppl 1</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Hepatitis C treatment for injection drug users: a review of the available evidence</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hellard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sacks-Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="561" to="573" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Genoway</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="270" to="277" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Lindenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Lambers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Urbanus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="23" to="31" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Effective treatment of injecting drug users with recently acquired hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hellard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Matthews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="123" to="135" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin</title>
		<author>
			<persName><forename type="first">M</forename><surname>Waizmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ackermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Subst Abuse Treat</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="338" to="345" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Melin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chousterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fontanges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1050" to="1057" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Integrated internistaddiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dimova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Marks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="47" to="54" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Van Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Molloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Friedlander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="900" to="906" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Treatment of hepatitis C infection in injection drug users</title>
		<author>
			<persName><forename type="first">M</forename><surname>Backmund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Zielonka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eichenlaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="188" to="193" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Follow-up studies of treatment for hepatitis C virus infection among injection drug users</title>
		<author>
			<persName><forename type="first">O</forename><surname>Dalgard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S336" to="338" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Treating hepatitis C in methadone maintenance patients: an interim analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sylvestre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="117" to="123" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b</title>
		<author>
			<persName><forename type="first">S</forename><surname>Neri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Abate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1627" to="1635" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Folwaczny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="443" to="451" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Van Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Anantharaju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Creech</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="2281" to="2288" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Goelz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schmutz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="120" to="124" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Treatment for hepatitis C virus infection among current injection drug users in Australia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Kronborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S325" to="329" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sylvestre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Litwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Gourevitch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Subst Abuse Treat</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="159" to="165" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Robaeys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Van Vlierberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Ranst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bruckers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buntinx</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="159" to="166" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Jeffrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Macquillan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chua</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="111" to="117" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes</title>
		<author>
			<persName><forename type="first">V</forename><surname>Guadagnino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Trotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Montesano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="423" to="431" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Raffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meagher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1519" to="1525" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Genoway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Khara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Drug Policy</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="437" to="443" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Hepatitis C treatment in &quot;difficult-to-treat&quot; psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hinzpeter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mohmand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="991" to="998" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bruggmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Falcato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dober</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="747" to="752" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Should active injecting drug users receive treatment for chronic hepatitis C?</title>
		<author>
			<persName><forename type="first">V</forename><surname>Papadopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gogou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mylopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mimidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arq Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="238" to="241" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C</title>
		<author>
			<persName><forename type="first">S</forename><surname>Manolakopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Deutsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Anagnostou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1454" to="1460" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tippet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="29" to="37" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C</title>
		<author>
			<persName><forename type="first">K</forename><surname>Jack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Willott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Manners</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Varnam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Thomson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="38" to="45" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection</title>
		<author>
			<persName><forename type="first">H</forename><surname>Jafferbhoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Dunbar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dillon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="112" to="119" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Factors associated with treatment failure of patients with psychiatric diseases and S134 • CID 2013:57 (Suppl 2) • Robaeys et al injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection</title>
		<author>
			<persName><forename type="first">G</forename><surname>Alvarez-Uria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Nasir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Vilar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1051" to="1055" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Dimova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeremski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Des</forename><surname>Jarlais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Talal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="806" to="816" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sasadeusz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kronborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yoshihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weltman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="977" to="984" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The management of chronic viral hepatitis: a Canadian consensus conference</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Villeneuve</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="715" to="728" />
			<date type="published" when="2004">2004. 2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Diagnosis, management, and treatment of hepatitis C: an update</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Ghany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Strader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Seeff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1335" to="1374" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">EASL clinical practice guidelines: management of hepatitis C virus infection</title>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="245" to="264" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Iversen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Topp</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999-2011. July</date>
		</imprint>
	</monogr>
	<note>published online ahead of print 1</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
		<idno type="DOI">10.1111/jvh.12129</idno>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Limited uptake of hepatitis C treatment among injection drug users</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Genberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Astemborski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Community Health</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="126" to="133" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Raffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="352" to="358" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Strathdee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Latka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S304" to="312" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Bird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="711" to="723" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cowie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="571" to="583" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Pouget</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Des</forename><surname>Jarlais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lelutiu-Weinberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="1099" to="1109" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The hepatitis C virus epidemic among injecting drug users</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">G</forename><surname>Pybus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cochrane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Simmonds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Genet Evol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="131" to="139" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Van Asten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Verhaest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lamzira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="292" to="302" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sievert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Altraif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Razavi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="61" to="80" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vickerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1978" to="1988" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Des Jarlais DC. A systematic review and metaanalysis of interventions to prevent hepatitis C virus infection in people who inject drugs</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Pouget</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="74" to="83" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="183" to="193" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vickerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hickman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1137" to="1144" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Micallef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kaldor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="34" to="41" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression</title>
		<author>
			<persName><forename type="first">A</forename><surname>John-Baptiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heathcote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Laporte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tomlinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="245" to="251" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Mortality in heroin-assisted treatment in Switzerland</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Frick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gutzwiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gschwend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Uchtenhagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="137" to="143" />
			<date type="published" when="1994">1994-2000. 2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Long-term methadone maintenance therapy: effects on liver function</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kreek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dodes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knobler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="598" to="602" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Petry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Piasecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Marsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Badger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Addict</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="265" to="269" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Ecstasy: a common cause of severe acute hepatotoxicity</title>
		<author>
			<persName><forename type="first">V</forename><surname>Andreu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bruguera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="394" to="397" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings</title>
		<author>
			<persName><forename type="first">E</forename><surname>Turillazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Riezzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fineschi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Pharm Biotechnol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="500" to="509" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Karch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Forensic Sci</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="359" to="368" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Bird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1150" to="1159" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Environmental factors as disease accelerators during chronic hepatitis C</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mallat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hezode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lotersztajn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="657" to="665" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hezode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Roudot-Thoraval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="63" to="71" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Influence of cannabis use on severity of hepatitis C disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="69" to="75" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Association of caffeine intake and histological features of chronic hepatitis C</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Costentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Roudot-Thoraval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Zafrani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1123" to="1129" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Increased caffeine consumption is associated with reduced hepatic fibrosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Modi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Feld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="201" to="209" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Shaheen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Myers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="2589" to="2600" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vergniol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Terrebonne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="e1" to="3" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Non-invasive markers for hepatic fibrosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Baranova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Birerdinc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Younossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">91</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Carrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Goldhaber-Fiebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e26783</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Outreach screening of drug users for cirrhosis with transient elastography</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Moessner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Jorgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Skamling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="970" to="976" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jullien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="121" to="131" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Management of HCV and HIV infections among people who inject drugs</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Tyndall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin HIV AIDS</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="501" to="507" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Barriers associated with the treatment of hepatitis C virus infection among illicit drug users</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Genoway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Raffa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="141" to="147" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs</title>
		<author>
			<persName><forename type="first">C</forename><surname>Treloar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bryant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hopwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lavis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="52" to="56" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals</title>
		<author>
			<persName><forename type="first">C</forename><surname>Treloar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Newland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hopwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="839" to="844" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Doab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Treloar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S313" to="320" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kanwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>El-Serag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="483" to="491" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Predictors of deferral of treatment for hepatitis C infection in Australian clinics</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Gidding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Amin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Aust</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="398" to="402" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Bini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Brau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Currie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1772" to="1779" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kanwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hoang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Spiegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1741" to="1749" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Natural history of chronic hepatitis C</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Seeff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S35" to="46" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>suppl 1</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Telaprevir for previously untreated chronic hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mchutchison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dusheiko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2405" to="2416" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Telaprevir for retreatment of HCV infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Andreone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2417" to="2428" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Boceprevir for untreated chronic HCV genotype 1 infection</title>
		<author>
			<persName><forename type="first">F</forename><surname>Poordad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mccone</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Bacon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="1195" to="1206" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Boceprevir for previously treated chronic HCV genotype 1 infection</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Bacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="1207" to="1217" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">A new standard of care for the treatment of chronic HCV infection</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="257" to="264" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1867" to="1877" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Sofosbuvir for previously untreated chronic hepatitis C infection</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mangia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wyles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1878" to="1887" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virological response (SVR12) in HCV genotype 1b-infected null responders</title>
		<author>
			<persName><forename type="first">K</forename><surname>Chayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawakami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">1428A</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Preliminary study of two antiviral agents for hepatitis C genotype 1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Lok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Gardiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="216" to="224" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">12-week interferon-free regimen of ABT-450/r+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders</title>
		<author>
			<persName><forename type="first">F</forename><surname>Poordad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="S549" to="S550" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Pharmacokinetic interaction between telaprevir and methadone</title>
		<author>
			<persName><forename type="first">R</forename><surname>Van Heeswijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vandevoorde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Verboven</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="2304" to="2309" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Abstract PK 09</title>
		<author>
			<persName><forename type="first">Egj</forename><surname>Hulskotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Bruce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Seventh International Workshop on Clinical Pharmacology of Hepatitis Therapy</title>
				<meeting><address><addrLine>Cambridge, MA</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2012-06">June 2012</date>
			<biblScope unit="page" from="27" to="28" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy</title>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trevejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Van Heeswijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="3641" to="3647" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Review article: adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Brau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stivala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fishbein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="14" to="27" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hellard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="76" to="85" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Adherence to treatment and quality of life during hepatitis C therapy: a prospective, reallife, observational study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Marcellin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chousterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fontanges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="516" to="524" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Assessing the validity of self-reported medication adherence in hepatitis C treatment</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Wahed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Conjeevaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Robuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Fried</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pharmacother</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1116" to="1123" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Adherence to hepatitis C treatment in recovering heroin users maintained on methadone</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sylvestre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="741" to="747" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Aspinall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Corson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Doyle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S80" to="89" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Adherence to hepatitis C virus therapy and early virologic outcomes</title>
		<author>
			<persName><surname>Lo Re V 3rd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Amorosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Localio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="186" to="193" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Poor response to hepatitis C virus (HCV) therapy in HIV-and HCV-coinfected patients is not due to lower adherence to treatment</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Galeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Montoliu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AIDS Res Hum Retroviruses</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="393" to="400" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cournot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glibert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Castel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterol Clin Biol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">6-7 Pt 1</biblScope>
			<biblScope unit="page" from="533" to="539" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Alcohol use and treatment of hepatitis C virus: results of a national multicenter study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Anand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Currie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dieperink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1607" to="1616" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bruggmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dampz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gerlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kravecz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Falcato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="167" to="171" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Management of mental health problems prior to and during treatment of HCV infection in patients with drug addiction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sarkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diez-Quevedo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S111" to="117" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Impact of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Matthews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="957" to="965" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Khosla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Aurora</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="942" to="947" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Kraus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schafer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Faller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Csef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Scheurlen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="708" to="714" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Evon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ramcharran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Belle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="2949" to="2958" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C</title>
		<author>
			<persName><forename type="first">F</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1049" to="1059" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Morasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychosomatics</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="500" to="505" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Models of care for the management of HCV among people who use drugs: one size does not fit all</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bruggmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Litwin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S56" to="61" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Hepatitis C virus reinfection following treatment among people who use drugs</title>
		<author>
			<persName><forename type="first">B</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schinkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dalgard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S105" to="110" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Treatment of acute HCV infection</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grebely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="265" to="274" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Coinfection with HIV and hepatitis C virus in injection drug users and minority populations</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Strader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S7" to="13" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b118">
	<monogr>
		<title/>
		<author>
			<persName><surname>S136 • Cid</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="page">57</biblScope>
		</imprint>
	</monogr>
	<note>Suppl 2) • Robaeys et al</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Sabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Friis-Moller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="1632" to="1641" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Management of HCV/HIV coinfection among people who use drugs in the era of direct-acting antiviralbased therapy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Matthews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S118" to="124" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brunette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Wolford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Marsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S26" to="33" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Torriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rodriguez-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rockstroh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="438" to="450" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Volberding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="451" to="459" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Z</forename><surname>Grimes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Q</forename><surname>Tran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="1500" to="1509" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="496" to="504" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>e3</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Kucirka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Farzadegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Feld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="845" to="852" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Current management of delta hepatitis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rizzetto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="195" to="197" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Gottardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Hilleret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gelez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="564" to="571" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection</title>
		<author>
			<persName><forename type="first">G</forename><surname>Robaeys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Starkel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="589" to="594" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Illicit drug use and liver transplantation: is there a problem and what is the solution?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Webb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Neuberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="923" to="929" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Liver transplantation for patients on methadone maintenance</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Kanchana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kaul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Manzarbeitia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="778" to="782" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
